Ostarine (also called MK-2866 or enobosarm) is a selective androgen receptor modulator, or SARM, that activates androgen receptors in muscle and bone while largely bypassing other tissues like the prostate, skin, and hair follicles. In clinical trials, doses as low as 3 mg per day increased lean body mass by about 1.4 kg over 12 weeks. It was developed as a potential treatment for muscle wasting conditions, but it has never been approved by the FDA for any use.
How Ostarine Works in the Body
Ostarine is a nonsteroidal compound that binds to androgen receptors, the same receptors that testosterone activates. The key difference from testosterone or anabolic steroids is tissue selectivity. Testosterone gets converted into other hormones once it enters the body: into estrogen in fat tissue and into DHT in the skin and prostate. Those conversions drive many of the unwanted effects of steroids, including prostate enlargement in men, masculinizing effects in women, and cardiovascular strain.
Ostarine skips those conversions. In animal studies, it increased muscle mass and bone density while actually reducing prostate size at the same doses that built muscle. This selective action is why SARMs attracted so much interest from pharmaceutical researchers looking for a way to treat muscle loss without the side effect profile of steroids.
Effects on Muscle and Strength
The most studied effect of ostarine is its ability to increase lean body mass. In a phase II trial of healthy elderly men and postmenopausal women, a 3 mg daily dose for 12 weeks produced an average gain of 1.4 kg of lean mass compared to placebo. That translated into meaningful functional improvements: participants climbed stairs 15.5% faster and generated 25.5% more power during the stair climb test. A separate phase II trial in cancer patients with cachexia (severe muscle wasting) also showed significant increases in lean mass and improved physical function over 16 weeks.
These are modest numbers compared to what anabolic steroids produce, but the gains came at very low doses in populations that were elderly or seriously ill. The doses commonly discussed in bodybuilding forums, typically 10 to 25 mg per day, are several times higher than what was studied in clinical trials. No controlled human research exists at those levels, so the risk-to-benefit ratio at recreational doses is essentially unknown.
Effects on Bone Density
Ostarine has shown protective effects on bone in animal models. In rats with induced osteoporosis, ostarine given as a preventive treatment maintained both cortical and trabecular bone density, performing comparably to testosterone. In the femur, cortical bone mineral density was significantly higher in ostarine-treated animals than in untreated controls. Earlier research in an ovariectomized rat model (simulating postmenopausal bone loss) found that ostarine increased bone mineral density and bone volume, and that preventive treatment improved fracture healing by increasing the size and density of the repair tissue.
One important nuance: when ostarine was given as a treatment after bone loss had already occurred rather than as prevention, results were weaker. Therapeutic dosing only improved cortical density in the femur while leaving other bone parameters unchanged, and it actually impaired fracture healing in some measures by reducing repair tissue and delaying bone bridging.
Side Effects and Health Risks
Ostarine is often marketed as a “mild” SARM, but clinical data show real physiological consequences even at low doses.
Cholesterol Changes
Ostarine suppresses HDL cholesterol (the protective kind) in a dose-dependent pattern. Over 12 weeks, the 1 mg dose lowered HDL by about 5 mg/dL, the 5 mg dose by about 13 mg/dL, and the 15 mg dose by about 18 mg/dL. LDL and triglycerides didn’t change significantly. A sustained drop in HDL raises cardiovascular risk over time, particularly for people already at risk for heart disease.
Hormonal Suppression
Because ostarine activates androgen receptors, it signals the body to reduce its own testosterone production. Animal data showed a roughly 20% reduction in serum testosterone. Research on a similar SARM in healthy men found reductions in total testosterone and sex hormone-binding globulin, though free testosterone and the hormones that drive testicular function (LH and FSH) were less affected. This means ostarine is suppressive, but less so than anabolic steroids. At higher recreational doses, suppression is likely more pronounced.
Liver Injury
In the phase II clinical trial at low doses, one participant had to discontinue due to liver enzyme levels rising to four times the normal upper limit. Seven others experienced smaller elevations that resolved while still taking the drug. More concerning is a published case of drug-induced liver injury in a man taking ostarine, confirmed by biopsy showing cholestatic damage, a pattern where bile flow from the liver becomes obstructed. The FDA has flagged life-threatening liver reactions, including acute liver failure, in people taking SARM-containing products.
Other Reported Risks
The FDA warning on SARM products lists additional potential harms: increased risk of heart attack or stroke, sleep disturbances, sexual dysfunction, infertility, testicular shrinkage, and in rare cases psychosis or hallucinations. Some of these may relate to contaminated or mislabeled products rather than ostarine specifically, but the lack of quality control in the unregulated supplement market makes that distinction meaningless for the end user.
Legal and Regulatory Status
Ostarine is not approved by the FDA for any medical use. Products containing it are not legally sold as dietary supplements, despite being widely marketed that way. The FDA has explicitly stated that these products are “unapproved drugs” that have not been reviewed for safety or effectiveness, and that they are “illegally marketed.”
In competitive sports, ostarine is banned across the board. The World Anti-Doping Agency lists it by name under “Other Anabolic Agents” on its Prohibited List, alongside other SARMs like ligandrol and RAD140. It is prohibited both in and out of competition. Ostarine has been the substance behind numerous doping violations in professional and amateur athletics, and athletes have been sanctioned even when they claimed exposure through contaminated supplements.
Why It’s Never Been Approved
Despite promising phase II results in muscle wasting, ostarine has not cleared the regulatory bar for approval. The clinical data showed real but modest benefits at low doses, paired with measurable side effects on cholesterol, liver enzymes, and hormonal balance. For a drug aimed at seriously ill cancer patients with cachexia, regulators weigh whether those tradeoffs are acceptable. For healthy people using it to build muscle, the calculus is different: there is no disease being treated, so any risk is harder to justify, and the long-term effects of months or years of use have never been studied in humans.
The products available online and in supplement stores carry an additional layer of risk. Independent testing has repeatedly found that SARM products contain doses different from what’s listed on the label, include unlisted active ingredients, or contain no SARM at all. Without pharmaceutical-grade manufacturing standards, what you’re actually ingesting is uncertain.